PT - JOURNAL ARTICLE AU - Redston, Mark AU - Noffsinger, Amy AU - Kim, Anthony AU - Akarca, Fahire G AU - Stapleton, Diane AU - Nowden, Laurel AU - Lash, Richard AU - Bass, Adam J AU - Stachler, Matthew D TI - Abnormal <em>TP53</em> predicts risk of progression in patients with Barrett’s esophagus regardless of a diagnosis of dysplasia AID - 10.1101/2020.10.18.20213561 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.18.20213561 4099 - http://medrxiv.org/content/early/2020/10/21/2020.10.18.20213561.short 4100 - http://medrxiv.org/content/early/2020/10/21/2020.10.18.20213561.full AB - Barrett’s esophagus is the precursor to esophageal adenocarcinomas, which are deadly cancers with a rapidly rising incidence. A major challenge is identifying the small group with Barrett’s esophagus who will progress to advanced disease from the many who will not. Assessment of p53 status has promise as a predictive biomarker, but analytic limitations and lack of validation in large, definitive studies have precluded its use. In this study, criteria for abnormal immunohistochemical expression of p53 were developed in non-dysplastic Barrett’s biopsies and validated with sequencing to assess TP53 mutations. The utility of p53 expression as a biomarker for progression of Barrett’s esophagus was tested retrospectively in 561 Barrett’s patients with or without known progression. The findings were prospectively validated in a clinical practice setting in 1487 Barrett’s patients. Abnormal p53 expression highly correlated with TP53 mutation status (90.6% agreement) and strongly associated with neoplastic progression in the retrospective cohorts, regardless of histologic diagnosis (P&lt;0.001). In patients with non-dysplastic Barrett’s esophagus at baseline, 89/179 (49.7%) of those with subsequent progression to high grade dysplasia/cancer and 3/179 (1.7%) of non-progressors had abnormal p53 (sensitivity: 49.7,% specificity: 98.3%, Odds ratio: 58 (95% CI 17.9-188.5, P&lt;0.0001) for identifying progressors). In the prospective validation cohort, p53 immunohistochemistry predicted progression among non-dysplastic Barrett’s, indefinite for dysplasia, and low-grade dysplasia (P&lt;0.001). p53 immunohistochemistry can successfully identify Barrett’s esophagus patients at high risk of progression, including in patients without evidence of dysplasia. p53 immunohistochemistry is inexpensive, easily integrated into routine practice, and should be considered in biopsies from all Barrett’s patients without high grade dysplasia or cancer.Competing Interest StatementThe authors have declared no competing interest.Funding StatementPrevent Cancer Foundation (MDS), Doris Duke Charitable Foundation (MDS), National Institutes of Health (AJB:U54CA163060; MDS:K08DK109209)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Inform Diagnostics Institutional Review Board reviewed and approved all studies within the manuscript.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data within the manuscript is available either within the manuscript or through communication with the authors.